Things Aren't Looking Great For Walgreen

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The nation's largest drugstore chain, Walgreen (NYSE: WAG  ) , saw its first-quarter profits drop 4.5%, largely because of the sluggish flu season and its imminent breakup with Express Scripts (Nasdaq: ESRX  ) . Its decision to discontinue operations with Express has cost Walgreen, sending shares down over 22% in the last six months. The two companies reached an impasse back in June, and their contract expired on Jan. 1. Let's delve a little deeper.

No colds, no income
Revenue crept up just 5% to $18.2 billion due to a meeker-than-expected cough, cold, and flu season. The number of flu shots Walgreen administered this year has dropped from a year ago. As of November 2011, it administered nearly 5 million shots, whereas at the same time last year, it had administered 5.6 million. Selling, general, and administrative expenses also rose by 5%, largely because of the acquisition of All this eventually resulted in the company's bottom line sliding down 4%.

But the major problem for the drug retailer is that for this next year it will not be filling the nearly 90 million Express Scripts prescriptions it did last fiscal year.

Express split
Sans Express, Walgreen will be without a pharmacy benefit manager, and to add to its woes, Express is set to join forces with Medco Health (NYSE: MHS  ) . The marriage between the two will create the largest pharmacy benefits operator in the U.S., and could result in Walgreen losing Medco customers over time.

As of last year, Express contributed $5.3 billion in revenue to Walgreen, which is roughly 7% of what Walgreen generated overall. Thus, it stands to lose a hefty chunk of its overall revenues without Express. This may work to the advantage of Walgreen's peers, as customers who are on the lookout for prescriptions can flock to nearby Rite Aid (NYSE: RAD  ) and CVS Caremark (NYSE: CVS  ) stores. With nearly a third of Rite Aid locations within a mile of a Walgreen, it should be a relatively easy switch for many customers to make. CVS, with its 7,304 retail drugstores, will also create a compelling switching case for many customers.

Impending loss
Walgreen said it may take a hit of $0.21 a share in the next fiscal year -- assuming that it can hold on to at least 25% of its customers with Express Scripts plans. Analysts expect that the breakup may cost Walgreen nearly $4 billion in revenue next year.

So, things aren't looking great for Walgreen. It will be interesting to see how the company copes without Express.

While 2012 may look bleak for Walgreen, there is one retailer we are absolutely giddy about. We love it so much that we've dubbed it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be forever, so click here to access it now.

Fool contributor Shubh Datta does not hold shares in any of the companies mentioned above. Motley Fool newsletter services have recommended buying shares of Medco Health Solutions. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 05, 2012, at 7:07 AM, JBKirtley wrote:

    Time will show that WAG has made the right choice by declining to discount 7% of their revenues to the point that the sales are not profitable. A loss is a loss and repetitive losses can never total into a gain. WAG's competitors will eventually realize that the only party making a profit under the ESRX contract is ESRX. WAG will end up with less gross sales but a higher margin on those sales. Smart business.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1751288, ~/Articles/ArticleHandler.aspx, 10/20/2016 8:37:47 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:00 PM
WBA $81.02 Up +3.84 +4.98%
Walgreens Boots Al… CAPS Rating: ****
CVS $87.30 Up +1.33 +1.54%
CVS Health CAPS Rating: ****
ESRX $71.04 Up +0.61 +0.87%
Express Scripts CAPS Rating: *****
MHS.DL $70.30 Down +0.00 +0.00%
Medco Health Solut… CAPS Rating: *****
RAD $7.11 Up +0.45 +6.76%
Rite Aid CAPS Rating: ****